Orion, Novartis divide entacapone markets
HELSINKI, Aug 26, 1998 (Reuters) - Finnish pharmaceuticals group Orion
said on Wednesday it had agreed with drug group Novartis on a
geographical division of markets for Orion's Parkinson's disease drug
entacapone.
``Orion will market the preparation in the Nordic and Baltic countries,
as well as in Germany, the UK and Ireland under the trademark Comtess.
Novartis will market the product in the other European countries and
elsewhere in the world under the trademark Comtan,'' Orion said in a
statement.
Applications for marketing authorization for entacapone are currently
under review by the European Union and U.S. drug authorities, Orion
said.
Entacapone is a COMT inhibitor developed by Orion and based on its own
molecule discovery, the company said.
It is used together with levodopa, which is a standard treatment for
Parkinson's disease patients, to enhance its effect, Orion said.
--
Judith Richards, London, Ontario, Canada
[log in to unmask]
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
